Mizuho Securities Starts Kura Oncology (KURA) at Buy, 'Large Opportunity in NPM1-m AML'

Mizuho Securities analyst Mara Goldstein initiates coverage on Kura Oncology (NASDAQ: KURA) with a Buy rating and a price target of $26.00.

The analyst comments "We initiate coverage of KURA with a Buy rating and $26 price target. The company is enrolling patients into a pivotal trial of ziftomenib, a menin inhibitor, in relapsed/refractory (r/r) NPM1-mutant (NPM1-m) acute myeloid leukemia (AML) monotherapy. Ziftomenib could be first-in-class in the NPM1-m population, a mutation present in 30% of AML diagnoses. Initial data raised questions around the difference in activity in the different AML populations, and we see data in 1Q24 as a value driver to begin to address this overhang and provide visibility on the potential for ziftomenib combination treatment in AML - potentially expanding the addressable market from $1+ billion to $3+ billion."

For an analyst ratings summary and ratings history on Kura Oncology click here. For more ratings news on Kura Oncology click here.

Shares of Kura Oncology closed at $12.57 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'